STOCK TITAN

Lemaitre Vasculr Stock Price, News & Analysis

LMAT Nasdaq

Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.

LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a provider of vascular devices, implants, and services for the treatment of peripheral vascular disease, with products developed for use by vascular surgeons. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow how LeMaitre’s vascular device business evolves over time.

In its regular quarterly updates, LeMaitre reports on net sales, gross margin, operating income, earnings per share, and geographic sales across the Americas, EMEA, and Asia Pacific. These releases often highlight which product categories, such as grafts, shunts, and catheters, are driving growth, and may call out specific products like the Artegraft biologic graft used in AV access and peripheral bypass. The company also discusses organic sales growth, adjusted profitability metrics, and the impact of pricing, volume, and manufacturing efficiencies.

Beyond earnings, LeMaitre issues news about dividends, share repurchase authorizations, and participation in healthcare and investor conferences hosted by firms such as Bank of America Securities, Wells Fargo, Morgan Stanley, and others. These events provide additional context on the company’s strategy, international expansion, and regulatory milestones, including launches of products like Artegraft in new markets.

Investors and observers can use this page to review historical press releases, monitor guidance updates, and see how management characterizes risks and opportunities in the peripheral vascular disease market. For ongoing coverage of LMAT news, this feed offers a centralized view of the company’s public communications and financial reporting.

Rhea-AI Summary

LeMaitre Vascular (Nasdaq:LMAT) announced management will participate in three investor conferences in Nov–Dec 2025.

  • Jefferies London Healthcare Conference — Tuesday, November 18, 2025 at 8:00 AM GMT at Waldorf Hilton, London; presenter: Dorian LeBlanc, CFO.
  • Wolfe Research 7th Annual Healthcare Conference — Wednesday, November 19, 2025 at 10:40 AM ET at Wolfe NYC Offices, New York; presenter: David Roberts, President.
  • Piper Sandler 37th Annual Healthcare Conference — Thursday, December 4, 2025 at 3:20 PM ET at Lotte Palace, New York; presenter: Dorian LeBlanc, CFO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
conferences
-
News
Rhea-AI Summary

LeMaitre Vascular (Nasdaq: LMAT) reported Q3 2025 results and raised guidance on Nov. 6, 2025. Q3 sales were $61.0mm (+11% overall, +12% organic). GAAP operating income was $20.3mm (+54%) and diluted EPS was $0.75 (+54%); non-GAAP adjusted operating income was $16.9mm (+29%) and adjusted EPS was $0.62 (+27%). Adjusted gross margin was 70.8% (up 300 bps). Cash rose by $23.6mm sequentially to $343.1mm. Growth drivers: grafts +23%, shunts +18%, Artegraft +33% (international launch). Regional sales: EMEA +18%, Americas +10%, APAC +4%. The board declared a quarterly dividend of $0.20/share payable Dec. 4, 2025, and authorized a $75.0mm share repurchase program through Feb. 17, 2026. Guidance: FY 2025 mid‑sales of $248mm (+13%) and adjusted full‑year operating income mid of $63.7mm.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
-
Rhea-AI Summary

LeMaitre Vascular (NASDAQ:LMAT) will release its third quarter 2025 financial results on Thursday, November 6, 2025 after the market close. A conference call to discuss results, business highlights, and outlook is scheduled the same day at 5:00 PM EST. Investors can register for live dial‑in access and a PIN or listen via a live audio webcast and replay at the company's investor site.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
Rhea-AI Summary

LeMaitre Vascular (Nasdaq:LMAT) announced its participation in four upcoming investor conferences in September 2025. CFO Dorian LeBlanc will represent the company at the Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 9), and the virtual Barrington Research Fall Investment Conference (Sept 16).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
conferences
-
News
Rhea-AI Summary

LeMaitre Vascular (Nasdaq: LMAT) reported strong Q2 2025 financial results with sales reaching $64.2 million, up 15% year-over-year. The company achieved notable performance metrics including a gross margin of 70.0% (up 110 bps), operating income of $16.1 million (up 12%), and earnings per diluted share of $0.60 (up 16%).

Growth was driven by strong performance in catheters (+27%) and grafts (+19%), with robust regional sales increases in EMEA (23%), Americas (12%), and APAC (12%). The company raised its 2025 guidance, announced a $0.20 quarterly dividend, and maintains an active $75.0 million share repurchase program through February 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.91%
Tags
-
Rhea-AI Summary

LeMaitre Vascular (Nasdaq:LMAT) has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close. The company will host a conference call at 5:00 PM EDT on the same day to discuss quarterly results, business highlights, and future outlook.

Investors can access the live call by registering online, after which they will receive dial-in information and a PIN. Additionally, an audio webcast will be available both live and for replay through the company's investor relations website at ir.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
Rhea-AI Summary

LeMaitre Vascular (NASDAQ:LMAT) announced that its President, David Roberts, will present at the Bank of America Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13, 2024, at 5:00 PM PDT and will take place at the Encore at the Wynn Hotel in Las Vegas, NV.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
conferences
-
News
Rhea-AI Summary
LeMaitre Vascular reported strong Q1 2025 financial results with sales reaching $59.9 million, up 12% (13% organic). The company achieved a gross margin of 69.2% and operating income of $12.6 million, up 6%. Earnings per share increased 10% to $0.48. Growth was driven by grafts (+17%) and carotid shunts (+14%), with EMEA sales up 18%. The company announced a $0.20 quarterly dividend and increased its 2025 guidance, now expecting sales of $245 million (+12%) and EPS of $2.16 (+12%). Notably, Artegraft received MDR CE Mark approval, enabling European market expansion. The company maintains a strong cash position of $302.5 million and has authorized a $75 million share repurchase program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.79%
Tags
-
Rhea-AI Summary

LeMaitre Vascular (NASDAQ:LMAT) has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025, after market close. The company will host a conference call at 5:00 PM EDT on the same day to discuss quarterly results, business highlights, and future outlook. Interested participants can access the live call by registering online, after which they will receive dial-in information and a PIN. Additionally, an audio webcast will be available both live and for replay through the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
Rhea-AI Summary

LeMaitre Vascular (Nasdaq: LMAT) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team is scheduled to deliver their presentation on Tuesday, April 8, 2025, at 3:45 PM EDT. This virtual event represents an opportunity for investors and healthcare industry stakeholders to gain insights into LeMaitre's operations and strategic initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
conferences

FAQ

What is the current stock price of Lemaitre Vasculr (LMAT)?

The current stock price of Lemaitre Vasculr (LMAT) is $87.51 as of February 3, 2026.

What is the market cap of Lemaitre Vasculr (LMAT)?

The market cap of Lemaitre Vasculr (LMAT) is approximately 2.0B.
Lemaitre Vasculr

Nasdaq:LMAT

LMAT Rankings

LMAT Stock Data

1.96B
20.87M
7.8%
95.11%
5.96%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
BURLINGTON

LMAT RSS Feed